FORMULATION AND INVESTIGATION OF POLYMERIC MULTIPLE UNIT PELLET SYSTEMS CONSISTING OF SUSTAINED RELEASE GLIMEPIRIDE AND IMMEDIATE RELEASE ATORVASTATIN CALCIUM

Objective: The objective of the present work was to develop novel fixed-dose combinations (FDCs) for improvement of glucose tolerance in type II diabetes mellitus patients associated with dyslipidemia. Methods: Multiple unit pellet systems (MUPSs) consisting of sustained release (SR) glimepiride and immediate release atorvastatin calcium pellets were formulated. The SR glimepiride pellets were prepared using a combination of locust bean gum and gum ghatti/guar gum. Similarly, the immediate release of atorvastatin calcium pellets was prepared using locust bean gum suspension as a binder. Results: The formulated pellets were characterized using Fourier transform infrared spectroscopy (FTIR) and Differential scanning calorimetry (DSC). Further, surface morphology of the formulated pellets was done by scanning electron microscopy (SEM). FT-IR and DSC studies suggested that there were no chemical interactions between the drug and natural polymers. SEM studies revealed that formulated pellets were in spherical shape. Based on in vitro evaluation, the SR glimepiride formulation developed using a combination of 2% locust bean gum and 2.5% gum ghatti polymers sustained the release of the drug up to 12 h. Similarly, the immediate release atorvastatin calcium formulation containing 1% w/w locust bean gum suspension as a binder and 7% croscarmellose sodium showed fast disintegration of pellets. The in vivo studies in albino Wistar rat revealed that there was an improvement in bioavailability of the drugs. Stability studies showed that there were no significant changes in the drug content and physical appearance of the prepared SR glimepiride and immediate release atorvastatin pellet formulations. Conclusion: Thus, the formulated FDC as MUPS can be used as an alternative approach for treating diabetes mellitus-induced dyslipidemia.

Download Full-text

FORMULATION OF IMMEDIATE RELEASE (IR) ATORVASTATIN CALCIUM PELLETS AND SUSTAINED RELEASE (SR) GLIBENCLAMIDE FOR FIXED-DOSE COMBINATION DOSAGE FORM

Asian Journal of Pharmaceutical and Clinical Research ◽

10.22159/ajpcr.2018.v11i12.26629 ◽

2018 ◽

Vol 11 (12) ◽

pp. 159

Author(s):

Kowshik K ◽

Vishal Gupta N ◽

Gowda Dv ◽

Praveen Sivadasu

Keyword(s):

Sustained Release ◽

Guar Gum ◽

Immediate Release ◽

Fixed Dose ◽

Locust Bean Gum ◽

Atorvastatin Calcium ◽

Dsc Studies ◽

Ft Ir ◽

Locust Bean

Objective: The objective of the present research was to develop fixed-dose combinations for the treatment of dyslipidemia, associated with type-II diabetes mellitus for improvement of glucose tolerance.Methods: Multiple unit pellet systems (MUPSs) consisting immediate release atorvastatin calcium pellets and sustained release glibenclamide were formulated by spheronization technique. The characterization of formulated pellets was done by Fourier transform infrared (FT-IR) and differential scanning calorimetry (DSC) studies, and formulated pellets were evaluated for solubility, viscosity, pH, and in vitro studies.Results: From FT-IR and DSC studies, it was confirmed that no chemical interaction existed between the drug and the natural polymers used. Solubility of glibenclamide was found to be 4.38 and 18.24 and atorvastatin calcium was found to be 6.84, 214.67, and 287.43 g/L. The viscosity of 1% w/v of locust bean gum, guar gum, and ghatti gum was found to be 169 cP, 124 cP, and 31 cP in distilled water. The pH of locust bean gum, guar gum, and gum ghatti solutions was found to be 5.6±0.49, 5.2±0.27, and 4.7±0.51. The in vitro studies suggested that glibenclamide pellets had shown a sustained release till 12 h, while atorvastatin calcium had shown immediate release of drug due to rapid disintegration of pellets.Conclusion: Thus, MUPS can be considered as an alternative approach to treat diabetes induced dyslipidemia.

Download Full-text

Design, Development and Optimization of Glibenclamide Sustained Release Matrix Tablet by Using Natural Polymers

Current Applied Polymer Science ◽

10.2174/2452271603666191104151057 ◽

2020 ◽

Vol 3 (3) ◽

pp. 197-211

Author(s):

Kuldeep H. Ramteke ◽

Dipika E. Ghadge ◽

Savita A. Palve ◽

Sachin S. Gaikwad

Keyword(s):

Drug Release ◽

Sustained Release ◽

Release Kinetics ◽

Matrix Tablets ◽

Locust Bean Gum ◽

Matrix Tablet ◽

Design Development ◽

Natural Polymers ◽

Drug Content ◽

Locust Bean

Background: Tablets being the conventional dosage forms can be modified for providing the desired therapeutic effect to the patients. The network of matrix in the tablet allows the drug release to be slowed down considerably. Objective: The prime objective of the study was to formulate sustained release glibenclamide matrix tablets using locust bean gum and karaya gum as a matrix polymer. Methods: Tablets were formulated by optimization using 32 factorial designs by direct compression method using different drug: polymer concentrations. The dependent variables selected were % cumulative drug release (Y1) and % drug content (Y2). The independent variables are the amount of locust bean gum (X1) and karayagum (X2). Drug-polymer compatibility studies were confirmed by FTIR and DSC. The pre-compression properties of powder were assessed indicating a good flow property. The evaluation results of the tablets were found to be within the Indian Pharmacopoeial limit. In this work, the effect of diluents type and polymer type was studied on the drug release with its increase in concentration. Results: All the formulations showed retarded drug release as the concentration of the polymer was increased. Formulation F8 was selected as the best-optimized formulation with about 100.56% drug release within 12 h. Release kinetics was carried out and it was found to be zero-order release and from assay, drug content was found to be in limits. Conclusion: ANOVA analysis indicated that the studied variables affected the response variables significantly. The optimized formulation was stable. Hence, it is concluded that the Glibenclamide sustained release matrix tablet containing natural polymers were successfully formulated by using 32 factorial design.

Download Full-text

DESIGN AND STATISTICAL OPTIMIZATION OF A BILAYERED TABLET OF METOPROLOL SUCCINATE SUSTAINED RELEASE AND ATORVASTATIN CALCIUM IMMEDIATE RELEASE: ONCE A DAY FORMULATION IN THE MANAGEMENT OF HYPERTENSION

Asian Journal of Pharmaceutical and Clinical Research ◽

10.22159/ajpcr.2018.v11i3.23528 ◽

2018 ◽

Vol 11 (3) ◽

pp. 293

Author(s):

Pearl Pires Dighe ◽

Tank Hm

Keyword(s):

Drug Release ◽

Sustained Release ◽

In Vitro Release ◽

Blood Cholesterol ◽

Fixed Dose ◽

Content Uniformity ◽

Metoprolol Succinate ◽

Atorvastatin Calcium ◽

Vitro Release

Objective: The current study involves the fabrication of oral bilayer matrix designs of a combination of two drugs, metoprolol succinate and atorvastatin calcium, the optimization of their in vitro release and characterization using the design expert software. Metoprolol succinate, a β1- selective adrenergic receptor blocking agent, is used in the management of hypertension has a half-life of approximately 4–5 h; thus, there is the need to use extended-release formulation for prolonged action. Atorvastatin is a hydroxymethylglutaryl-coenzyme A reductase inhibitor, an antilipidemic, used to lower blood cholesterol. The rationale for this fixed-dose combination is to coadminister two drugs acting by different mechanisms of action together, reduce dosing frequency, and increase patient compliance.Methods: A 32 factorial design was selected to analyze the effect of critical factors, polymer concentration of Kollidon sustained release (SR), and Eudragit RS and their interaction on the in vitro release of the SR part containing metoprolol succinate. The drug release at 2 h (Q2), 8 h (Q8), and 20 h (Q20) was taken as responses. The blends of both layers were prepared, evaluated for precompression characteristics, and compressed by direct compression. The compressed bilayer tablets were evaluated for their hardness, weight variation, friability, content uniformity, diameter, and in vitro release.Result and Conclusion: The release profile indicates Higuchi’s kinetics. Contour and surface response plots show significant interaction among the formulation variables. Formulation MS06 containing 70 mg Kollidon SR and 10 mg Eurdragit RS was found to be the optimized formulation, controlling the drug release for a 24 h period.

Download Full-text